Wealthtrust Axiom Llc owns 1.00 million shares or 2.28% of their U.S. portfolio. The value of the total investment in Ascendis Pharma A/S – American increased from $12,029,000 to $15,653,000 increasing 30.1% quarter to quarter. As of quarter end Foresite Capital Management Iii, LLC had disposed of a total of 77,600 shares trimming its stake by 77.6%. The biotechnology company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.24). VHCP Management II LLC now owns 811,492 shares of the biotechnology company’s stock valued at $22,722,000 after buying an additional 90,340 shares during the last quarter. Vhcp Management Ii, LLC added to its position by buying 175,000 shares an increase of 21.6% in the quarter. Eventide Asset Management LLC now owns 246,100 shares of the biotechnology company’s stock worth $6,891,000 after purchasing an additional 17,100 shares in the last quarter.
Several other equities analysts also recently weighed in on the stock.
Investors sold shares of Ascendis Pharma A/S (NASDAQ:ASND) on strength during trading hours on Friday. Separately, Wedbush’s Liana Moussatos reiterated a Buy rating on the stock, while boosting the price target to $65 (from $36). Finally, ValuEngine raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Saturday, May 27th. The stock of Ascendis Pharma A S (NASDAQ:ASND) earned “Buy” rating by Wedbush on Monday, September 11. The stock now has an average rating of Hold and an average target price of $33.29.
About 103,310 shares traded. Finally, Leerink Swann reissued a hold rating and issued a $28.00 target price on shares of Ascendis Pharma A/S in a report on Friday, September 1st. Ascendis Pharma A S (NASDAQ:ASND) has risen 96.01% since September 23, 2016 and is uptrending. This indicates more upside for the $1.26 billion company. Ascendis Pharma A/S had a negative net margin of 2,977.70% and a negative return on equity of 67.76%. On average, equities analysts forecast that Ascendis Pharma A/S will post ($0.17) EPS for the current year. The business’s revenue was down 61.4% on a year-over-year basis.
Analysts expect Ascendis Pharma A S (NASDAQ:ASND) to report $-0.84 EPS on November, 29.They anticipate $0.04 EPS change or 5.00 % from last quarter’s $-0.8 EPS. More interesting news about Ascendis Pharma A S (NASDAQ:ASND) were released by: Prnewswire.com and their article: “Ascendis Pharma A/S Reports First Quarter 2017 Financial Results” published on May 23, 2017 as well as Prnewswire.com’s news article titled: “Ascendis Pharma A/S Announces Updated Time for April 3 Conference Call to …” with publication date: March 31, 2017. If you are accessing this article on another publication, it was copied illegally and republished in violation of usa and global copyright and trademark legislation.
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies to address markets with unmet medical needs. Specifically, Versartis Inc’s (NASDAQ:VSAR) lead candidate, somavaratan, failed to achieve non-inferiority in the ITT population for the Phase 3 VELOCITY trial in Pediatric Growth Hormone Deficiency (GHD), based on higher-than-expected growth velocity for the Genotropin arm.